Pulmonary Arterial Hypertension Market Size, Share & Trends Analysis Report By Drug Class (Prostacyclin And Prostacyclin Analogs, SGC Stimulators, ERA, PDE-5), By Region, And Segment Forecasts, 2021 - 2028

Report Overview

The global pulmonary arterial hypertension market size was valued at USD 5.3 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 4.9% from 2021 to 2028. The market is expected to witness significant growth over the forecast period owing to the increasing incidence of PAH (pulmonary arterial hypertension), the growing geriatric population, and rising government support to develop orphan drugs. Cumulatively, the cases of PAH are in the range of 100,000 to 200,000 per year. However, in the past few years, the prevalence of PAH is increasing due to various factors, such as sedentary lifestyle, increase in the incidence of HIV, rise in smoking and alcohol/tobacco consumption, and other idiopathic conditions. Pulmonary arterial hypertension patients are at a higher risk of suffering from COVID-19. According to the American College of Cardiology, as of August 2020, the incidence rate of COVID-19 infection in PAH patients was 2.1 cases per 1,000 patients. This increased the demand for PAH drugs for its treatment to manage the risk of COVID-19 infection. This demand positively impacted the market growth.

Market players are investing in product launches and collaborations to gain a competitive edge in the market. For instance, in February 2021, United Therapeutics commercially launched a Remunity pump for Remodulin to treat pulmonary arterial hypertension. This device is small, compact, and preloaded with medication, providing superior outcomes compared to current subcutaneous pump solutions. This is anticipated to positively affect the overall market growth over the forecast period.

The global prevalence of PAH is very low, which is around 15 to 50 cases per million, hence, it is classified as a rare disorder. Cumulatively, the cases of PAH are in the range of 100,000 to 200,000 per year. However, in the past few years, the prevalence of this disorder is rising due to the risk factors like sedentary lifestyle, HIV, smoking, alcohol/tobacco consumption, and other idiopathic conditions. Therefore, the rising prevalence of PAH is also expected to boost the market growth during the forecast period.

COVID19 pulmonary arterial hypertension market impact: marginal growth of 2% from 2019 to 2020

The presence of a large population over 60 years, which has lower immunity levels and is prone to PAH and associated diseases, is a high impact-rendering factor for the growth of the PAH market over the forecast period. Although the onset age for PAH is 45 years, it is frequently observed to occur in the population above 60 years of age. This population is expected to avail the best possible treatments, increasing the life span. This could be the potential target group contributing to the increasing demand for PAH drugs.

Drug Class Insights

The prostacyclin and prostacyclin analogs segment captured the largest share of over 45.0% in 2020 owing to the high demand for these drugs. Drugs from the prostacyclin and analogs segment are expected to grow significantly over the forecast period, primarily due to the opportunities presented in the oral prostacyclin sub-segment (e.g. Uptravi and Orenitram).

The SGC simulators segment is expected to expand at the fastest CAGR of 12.3% from 2021 to 2028. sGC stimulators can ensure maximum activation of sGC by potentiating NO-sGC signaling. Riociguat (Adempas from Bayer) is the only drug approved for PAH in this category. The ERA and PDE-5 segments are expected to witness significant growth during the forecast period.

Regional Insights

North America dominated the market with a share of over 55.0% in 2020 due to the developed healthcare infrastructure in the U.S. that facilitated access to advanced therapeutics. In addition, increased awareness, a high diagnosis rate, and supportive government initiatives governed the growth of this regional market. A well-planned reimbursement structure and high awareness resulted in an excellent diagnosis rate. Besides, supportive legislations like Rare Disease Act 2002 and the Orphan Drug Act (ODA) 1983, in the U.S. fostered the development of novel medication for PAH.

Europe followed North America with agencies such as the European Medicines Agency (EMA) and the European Society of Cardiology promoting early and preventive diagnosis of PAH. The increasing prevalence of risk factors and associated diseases, such as HIV, is increasing the probability of the development of PAH. Moreover, the rising geriatric population, lifestyle changes, and pollution are anticipated to contribute to the increasing prevalence of PAH in Europe.

Asia Pacific is anticipated to expand at the fastest CAGR of 5.9% over the forecast period. This can be attributed to the improving healthcare systems, rapid economic developments, and a large population base. In addition, the high burden of diseases, such as HIV and diabetes, which are responsible for the development of the PAH, supports the market growth in this region.

Key Companies & Market Share Insights

The market is highly competitive with the presence of many large-scale and small-scale players. Key strategies undertaken by the market players to build a strong foothold in the market include new product development, collaborations, and geographical expansion. For instance, in October 2020, Johnson & Johnson acquired Momenta Pharmaceuticals, Inc. for about USD 6.5 billion. This acquisition strengthened J&J’s position in the autoimmune diseases market. Some prominent players in the global pulmonary arterial hypertension market include:

• Johnson & Johnson Services, Inc.

• United Therapeutics Corporation

• Pfizer, Inc.

• Acceleron Pharma, Inc.

• Gilead Sciences, Inc.

• Bayer AG

• GlaxoSmithKline Plc. (GSK) 

Pulmonary Arterial Hypertension Market Report Scope

Segments Covered in the Report

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2016 to 2028. For the purpose of this study, Grand View Research, Inc. has segmented the global pulmonary arterial hypertension market report on the basis of drug class and region:

• Drug Class Outlook (Revenue, USD Million, 2016 - 2028)

  • Prostacyclin and Prostacyclin Analogs

  • Soluble Guanylate Cyclase (SGC) Stimulators

  • Endothelin Receptor Antagonist (ERA)

  • Phosphodiesterase 5 (PDE-5)

• Regional Outlook (Revenue, USD Million, 2016 - 2028)

  • North America

    • U.S.

    • Canada

  • Europe

    • U.K.

    • Germany

    • Italy

    • Spain

    • France

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East and Africa (MEA)

    • South Africa

    • Saudi Arabia

    • UAE